On October 15th, NovoCure Limited received FDA approval of its lung cancer treatment. Read why I upgrade NVCR stock from buy ...

Optune Lua for concurrent use with PD-1/PD-L1 inhibitors or docetaxel for adult patients with metastatic non-small cell lung ...

Novocure received a long-sought FDA approval for the use of its Tumor Treating Fields technology against metastatic non-small ...

ASML extends losses after cutting sales guidance, Nvidia stock edges higher, and third-quarter adjusted earnings at United ...

Optune Lua received FDA approval based on data from the pivotal LUNAR trial which demonstrated significant median OS ...

Novocure announced on Tuesday that the FDA treated its Optune Lua wearable device for treating metastatic non-small cell lung ...

Novocure (NASDAQ: NVCR) announced today that the U.S. Food and Drug Administration (FDA) has approved Optune Lua® for ...

Alongside immunotherapy or chemo, the wearable device helped patients live longer in a trial, though the results are somewhat controversial.

Novocure (NVCR) shares rise 6% after FDA approval for Optune Lua in treating metastatic non-small cell lung cancer.

The FDA yesterday the approval of Novocure’s Optune device to include the treatment of metastatic non-small cell lung cancer.